Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Vanda Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.

Get VNDA alerts

About Gunther Birznieks

The proxy statement of Vanda Pharmaceuticals Inc. reports total compensation of $1,415,471 for Gunther Birznieks in fiscal 2025, including a base salary of $559,935. Disclosed compensation is on record for 9 fiscal years. Vanda Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vanda Pharmaceuticals Inc. includes Mihael Polymeropoulos (CEO and Board Member), Kevin Moran (CFO), Anne Sempowski Ward (Board Member) and 6 others.

Affiliation history

Company network

Leadership on record at Vanda Pharmaceuticals Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Vanda Pharmaceuticals Inc. (VNDA) $559,935 $1,415,471
2024 Vanda Pharmaceuticals Inc. (VNDA) $541,000 $1,423,438
2023 Vanda Pharmaceuticals Inc. (VNDA) $520,000 $1,373,008
2022 Vanda Pharmaceuticals Inc. (VNDA) $460,040 $1,471,317
2021 Vanda Pharmaceuticals Inc. (VNDA) $434,000 $2,000,853
2020 Vanda Pharmaceuticals Inc. (VNDA) $421,000 $1,377,808
2019 Vanda Pharmaceuticals Inc. (VNDA) $386,250 $2,010,821
2018 Vanda Pharmaceuticals Inc. (VNDA) $375,000 $1,873,006
2017 Vanda Pharmaceuticals Inc. (VNDA) $325,000 $2,098,792

Recent activity

No call appearances or filed executive changes recorded yet.